MDXH News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MD

Mkt Cap

$19.8M

Volume

16.39M

Next Earnings

November 11th

Loading chart

MD

MDXHMDxHealth SA Ordinary Shares

MDXH

Pay with—

Available Balance0.00

MD

Mkt Cap

$19.7M

Volume

16.39M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities DeficiencyMdxhealth SA (NASDAQ: MDXH) received a notification from Nasdaq on July 20, 2026, indicating non-compliance with the minimum market value requirement of $35 million for continued listing on The Nasdaq Capital Market. The company has until January 19, 2027 (180 calendar days) to regain compliance by achieving a market value exceeding $35 million for at least 10 consecutive business days. The deficiency does not currently impact the company's listing status, and business operations remain unaffected.GlobeNewswire Inc. · Jul 24, 2026

Mdxhealth Reports Q1-2026 ResultsMdxhealth (NASDAQ: MDXH) reported Q1-2026 revenue of $27.4 million, up 13% year-over-year, but announced the discontinuation of its Resolve UTI business and Plano, Texas laboratory operations due to uncertain reimbursement landscape and a Medicare policy reversal. The company is refocusing on its core prostate cancer diagnostics business and establishing updated 2026 guidance of $110-115 million in revenue (20-26% YoY growth). The company also faces a $10.4 million Medicare recoupment decision from Novitas that it is contesting.GlobeNewswire Inc. · May 13, 2026

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026Mdxhealth announced positive data from the GPS-ProMPT study at the EAU Congress, demonstrating that its Genomic Prostate Score (GPS mdx) test successfully stratified treatment failure risk across multiple prostate cancer treatment pathways. The study of 409 patients showed excellent six-year freedom-from-failure outcomes (92-100%), supporting the test's ability to identify patients with favorable tumor biology for treatment de-escalation. The company is advancing collaboration with University of Oxford on the GPS-ProtecT study to establish GPS mdx as the first genomic classifier supported by randomized clinical trial evidence.GlobeNewswire Inc. · Mar 16, 2026

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26MDxHealth SA (NASDAQ: MDXH), a precision diagnostics company, announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, followed by a conference call. The company also reported preliminary 2025 revenues, issued 2026 guidance, and amended earnout terms with Exact Sciences. Additionally, MDxHealth is collaborating with the University of Oxford to validate its GPS test in a large randomized trial for localized prostate cancer treatment.GlobeNewswire Inc. · Feb 12, 2026

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact SciencesMDxHealth reported preliminary 2025 revenues of $109 million (21% YoY growth) with Q4 revenues of $30.5 million (23% YoY growth). The company issued 2026 revenue guidance of $137-140 million (26-28% growth) and expects to achieve a 10% adjusted EBITDA margin run rate by year-end 2026. MDxHealth amended its earnout obligations with Exact Sciences, deferring payments to 2026-2028 and issuing 3 million warrant shares at $5.265 per share.GlobeNewswire Inc. · Jan 12, 2026

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancerMdxhealth announced a collaboration with the University of Oxford to initiate Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial, the world's largest randomized clinical trial for localized prostate cancer treatment. This study aims to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, potentially impacting clinical practice guidelines and payer coverage.GlobeNewswire Inc. · Jan 6, 2026

Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-TechneMDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.Benzinga · Sep 15, 2025

Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management ChangeMDxHealth appointed Michael Holder to its Board of Directors as Audit Committee Chair, replacing Regine Slagmulder. CFO Ron Kalfus is resigning, with Scott McMahan assuming interim CFO responsibilities.GlobeNewswire Inc. · Jul 3, 2025

Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsightThe molecular diagnostics market is experiencing significant growth driven by advancements in technology, increasing demand for personalized medicine, and the rising prevalence of chronic diseases. Innovations such as next-generation sequencing (NGS) and PCR-based testing are expanding the scope of molecular diagnostics, enabling early detection and more accurate diagnoses.GlobeNewswire Inc. · May 1, 2025

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand WorldwideThe Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.GlobeNewswire Inc. · Apr 8, 2025

to start trading

MD

MDXHMDxHealth SA Ordinary Shares

MDXH

Pay with—

Available Balance0.00

Your PositionYou don't own any MDXH yet.

Related Tickers

Earnings